nodes	percent_of_prediction	percent_of_DWPC	metapath
Indinavir—SLC22A1—Cytarabine—lymphatic system cancer	0.112	0.139	CbGbCtD
Indinavir—ABCC1—Mitoxantrone—lymphatic system cancer	0.0981	0.122	CbGbCtD
Indinavir—ABCC1—Vincristine—lymphatic system cancer	0.0675	0.0838	CbGbCtD
Indinavir—CYP3A5—Teniposide—lymphatic system cancer	0.052	0.0646	CbGbCtD
Indinavir—ABCC2—Vincristine—lymphatic system cancer	0.05	0.0621	CbGbCtD
Indinavir—CYP2C19—Teniposide—lymphatic system cancer	0.042	0.0521	CbGbCtD
Indinavir—ABCC1—Methotrexate—lymphatic system cancer	0.0409	0.0508	CbGbCtD
Indinavir—SLCO1A2—Methotrexate—lymphatic system cancer	0.0365	0.0453	CbGbCtD
Indinavir—CYP2C9—Teniposide—lymphatic system cancer	0.0349	0.0433	CbGbCtD
Indinavir—SLCO1B1—Methotrexate—lymphatic system cancer	0.0344	0.0428	CbGbCtD
Indinavir—CYP3A7—Vincristine—lymphatic system cancer	0.0334	0.0414	CbGbCtD
Indinavir—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0334	0.0414	CbGbCtD
Indinavir—ABCC2—Methotrexate—lymphatic system cancer	0.0303	0.0376	CbGbCtD
Indinavir—CYP3A5—Vincristine—lymphatic system cancer	0.025	0.0311	CbGbCtD
Indinavir—ABCB1—Mitoxantrone—lymphatic system cancer	0.0237	0.0294	CbGbCtD
Indinavir—CYP3A4—Cytarabine—lymphatic system cancer	0.0206	0.0256	CbGbCtD
Indinavir—CYP3A4—Teniposide—lymphatic system cancer	0.0203	0.0252	CbGbCtD
Indinavir—ABCB1—Vincristine—lymphatic system cancer	0.0163	0.0202	CbGbCtD
Indinavir—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0142	0.0176	CbGbCtD
Indinavir—ABCB1—Methotrexate—lymphatic system cancer	0.00987	0.0122	CbGbCtD
Indinavir—CYP3A4—Vincristine—lymphatic system cancer	0.00976	0.0121	CbGbCtD
Indinavir—Paraesthesia—Fludarabine—lymphatic system cancer	0.000393	0.00202	CcSEcCtD
Indinavir—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000392	0.00202	CcSEcCtD
Indinavir—Sweating—Mitoxantrone—lymphatic system cancer	0.000391	0.00201	CcSEcCtD
Indinavir—Dyspnoea—Fludarabine—lymphatic system cancer	0.00039	0.00201	CcSEcCtD
Indinavir—Haematuria—Mitoxantrone—lymphatic system cancer	0.000389	0.002	CcSEcCtD
Indinavir—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000387	0.00199	CcSEcCtD
Indinavir—Dyspepsia—Fludarabine—lymphatic system cancer	0.000385	0.00198	CcSEcCtD
Indinavir—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000383	0.00197	CcSEcCtD
Indinavir—Decreased appetite—Fludarabine—lymphatic system cancer	0.00038	0.00196	CcSEcCtD
Indinavir—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000378	0.00194	CcSEcCtD
Indinavir—Fatigue—Fludarabine—lymphatic system cancer	0.000377	0.00194	CcSEcCtD
Indinavir—Inflammation—Methotrexate—lymphatic system cancer	0.000375	0.00193	CcSEcCtD
Indinavir—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000374	0.00193	CcSEcCtD
Indinavir—Constipation—Fludarabine—lymphatic system cancer	0.000374	0.00193	CcSEcCtD
Indinavir—Pain—Fludarabine—lymphatic system cancer	0.000374	0.00193	CcSEcCtD
Indinavir—Vasculitis—Methotrexate—lymphatic system cancer	0.000373	0.00192	CcSEcCtD
Indinavir—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000372	0.00191	CcSEcCtD
Indinavir—Respiratory failure—Methotrexate—lymphatic system cancer	0.00037	0.0019	CcSEcCtD
Indinavir—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00037	0.0019	CcSEcCtD
Indinavir—Urethral disorder—Vincristine—lymphatic system cancer	0.000369	0.0019	CcSEcCtD
Indinavir—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000368	0.00189	CcSEcCtD
Indinavir—Hypersensitivity—Teniposide—lymphatic system cancer	0.000367	0.00189	CcSEcCtD
Indinavir—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000367	0.00189	CcSEcCtD
Indinavir—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000367	0.00189	CcSEcCtD
Indinavir—Flushing—Carmustine—lymphatic system cancer	0.000366	0.00188	CcSEcCtD
Indinavir—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000365	0.00188	CcSEcCtD
Indinavir—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000364	0.00187	CcSEcCtD
Indinavir—Anaemia—Bleomycin—lymphatic system cancer	0.000363	0.00187	CcSEcCtD
Indinavir—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000361	0.00186	CcSEcCtD
Indinavir—Asthenia—Teniposide—lymphatic system cancer	0.000357	0.00184	CcSEcCtD
Indinavir—Malaise—Bleomycin—lymphatic system cancer	0.000355	0.00182	CcSEcCtD
Indinavir—Pruritus—Teniposide—lymphatic system cancer	0.000352	0.00181	CcSEcCtD
Indinavir—Alopecia—Carmustine—lymphatic system cancer	0.000348	0.00179	CcSEcCtD
Indinavir—Body temperature increased—Fludarabine—lymphatic system cancer	0.000346	0.00178	CcSEcCtD
Indinavir—Malnutrition—Carmustine—lymphatic system cancer	0.000343	0.00177	CcSEcCtD
Indinavir—Cough—Bleomycin—lymphatic system cancer	0.000343	0.00176	CcSEcCtD
Indinavir—Diarrhoea—Teniposide—lymphatic system cancer	0.000341	0.00175	CcSEcCtD
Indinavir—Chest pain—Bleomycin—lymphatic system cancer	0.000335	0.00172	CcSEcCtD
Indinavir—Myalgia—Bleomycin—lymphatic system cancer	0.000335	0.00172	CcSEcCtD
Indinavir—Alopecia—Vincristine—lymphatic system cancer	0.000333	0.00171	CcSEcCtD
Indinavir—Back pain—Carmustine—lymphatic system cancer	0.000332	0.00171	CcSEcCtD
Indinavir—Discomfort—Bleomycin—lymphatic system cancer	0.000331	0.0017	CcSEcCtD
Indinavir—Chills—Mitoxantrone—lymphatic system cancer	0.000329	0.00169	CcSEcCtD
Indinavir—Alopecia—Mitoxantrone—lymphatic system cancer	0.000324	0.00167	CcSEcCtD
Indinavir—Vision blurred—Carmustine—lymphatic system cancer	0.000323	0.00166	CcSEcCtD
Indinavir—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000322	0.00166	CcSEcCtD
Indinavir—Tremor—Carmustine—lymphatic system cancer	0.000322	0.00165	CcSEcCtD
Indinavir—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000321	0.00165	CcSEcCtD
Indinavir—Oedema—Bleomycin—lymphatic system cancer	0.000321	0.00165	CcSEcCtD
Indinavir—Anaemia—Carmustine—lymphatic system cancer	0.000317	0.00163	CcSEcCtD
Indinavir—Back pain—Vincristine—lymphatic system cancer	0.000317	0.00163	CcSEcCtD
Indinavir—Vomiting—Teniposide—lymphatic system cancer	0.000317	0.00163	CcSEcCtD
Indinavir—Agitation—Carmustine—lymphatic system cancer	0.000315	0.00162	CcSEcCtD
Indinavir—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000314	0.00162	CcSEcCtD
Indinavir—Asthenia—Fludarabine—lymphatic system cancer	0.000314	0.00162	CcSEcCtD
Indinavir—Rash—Teniposide—lymphatic system cancer	0.000314	0.00162	CcSEcCtD
Indinavir—Dermatitis—Teniposide—lymphatic system cancer	0.000314	0.00161	CcSEcCtD
Indinavir—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000312	0.00161	CcSEcCtD
Indinavir—Headache—Teniposide—lymphatic system cancer	0.000312	0.0016	CcSEcCtD
Indinavir—Pruritus—Fludarabine—lymphatic system cancer	0.00031	0.00159	CcSEcCtD
Indinavir—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000309	0.00159	CcSEcCtD
Indinavir—Back pain—Mitoxantrone—lymphatic system cancer	0.000309	0.00159	CcSEcCtD
Indinavir—Anorexia—Bleomycin—lymphatic system cancer	0.000306	0.00157	CcSEcCtD
Indinavir—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000303	0.00156	CcSEcCtD
Indinavir—Anaemia—Vincristine—lymphatic system cancer	0.000303	0.00156	CcSEcCtD
Indinavir—Agitation—Vincristine—lymphatic system cancer	0.000301	0.00155	CcSEcCtD
Indinavir—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000301	0.00155	CcSEcCtD
Indinavir—Diarrhoea—Fludarabine—lymphatic system cancer	0.000299	0.00154	CcSEcCtD
Indinavir—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000296	0.00152	CcSEcCtD
Indinavir—Nausea—Teniposide—lymphatic system cancer	0.000296	0.00152	CcSEcCtD
Indinavir—Anaemia—Mitoxantrone—lymphatic system cancer	0.000295	0.00152	CcSEcCtD
Indinavir—Vertigo—Vincristine—lymphatic system cancer	0.000294	0.00151	CcSEcCtD
Indinavir—Hepatic failure—Methotrexate—lymphatic system cancer	0.000294	0.00151	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000292	0.0015	CcSEcCtD
Indinavir—Myalgia—Carmustine—lymphatic system cancer	0.000292	0.0015	CcSEcCtD
Indinavir—Chest pain—Carmustine—lymphatic system cancer	0.000292	0.0015	CcSEcCtD
Indinavir—Anxiety—Carmustine—lymphatic system cancer	0.000291	0.0015	CcSEcCtD
Indinavir—Paraesthesia—Bleomycin—lymphatic system cancer	0.000288	0.00148	CcSEcCtD
Indinavir—Malaise—Mitoxantrone—lymphatic system cancer	0.000288	0.00148	CcSEcCtD
Indinavir—Dyspnoea—Bleomycin—lymphatic system cancer	0.000286	0.00147	CcSEcCtD
Indinavir—Renal failure acute—Methotrexate—lymphatic system cancer	0.000286	0.00147	CcSEcCtD
Indinavir—Oedema—Carmustine—lymphatic system cancer	0.00028	0.00144	CcSEcCtD
Indinavir—Decreased appetite—Bleomycin—lymphatic system cancer	0.000279	0.00143	CcSEcCtD
Indinavir—Myalgia—Vincristine—lymphatic system cancer	0.000279	0.00143	CcSEcCtD
Indinavir—Cough—Mitoxantrone—lymphatic system cancer	0.000278	0.00143	CcSEcCtD
Indinavir—Vomiting—Fludarabine—lymphatic system cancer	0.000278	0.00143	CcSEcCtD
Indinavir—Rash—Fludarabine—lymphatic system cancer	0.000276	0.00142	CcSEcCtD
Indinavir—Dermatitis—Fludarabine—lymphatic system cancer	0.000276	0.00142	CcSEcCtD
Indinavir—Pain—Bleomycin—lymphatic system cancer	0.000274	0.00141	CcSEcCtD
Indinavir—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000274	0.00141	CcSEcCtD
Indinavir—Headache—Fludarabine—lymphatic system cancer	0.000274	0.00141	CcSEcCtD
Indinavir—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000273	0.0014	CcSEcCtD
Indinavir—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000272	0.0014	CcSEcCtD
Indinavir—Chest pain—Mitoxantrone—lymphatic system cancer	0.000272	0.0014	CcSEcCtD
Indinavir—Myalgia—Mitoxantrone—lymphatic system cancer	0.000272	0.0014	CcSEcCtD
Indinavir—Anxiety—Mitoxantrone—lymphatic system cancer	0.000271	0.00139	CcSEcCtD
Indinavir—Discomfort—Mitoxantrone—lymphatic system cancer	0.000268	0.00138	CcSEcCtD
Indinavir—Oedema—Vincristine—lymphatic system cancer	0.000267	0.00138	CcSEcCtD
Indinavir—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000267	0.00138	CcSEcCtD
Indinavir—Anorexia—Carmustine—lymphatic system cancer	0.000267	0.00137	CcSEcCtD
Indinavir—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000264	0.00136	CcSEcCtD
Indinavir—Nervous system disorder—Vincristine—lymphatic system cancer	0.000262	0.00135	CcSEcCtD
Indinavir—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000262	0.00135	CcSEcCtD
Indinavir—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00026	0.00134	CcSEcCtD
Indinavir—Oedema—Mitoxantrone—lymphatic system cancer	0.00026	0.00134	CcSEcCtD
Indinavir—Nausea—Fludarabine—lymphatic system cancer	0.00026	0.00134	CcSEcCtD
Indinavir—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000258	0.00133	CcSEcCtD
Indinavir—Shock—Mitoxantrone—lymphatic system cancer	0.000256	0.00132	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000255	0.00131	CcSEcCtD
Indinavir—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000255	0.00131	CcSEcCtD
Indinavir—Urticaria—Bleomycin—lymphatic system cancer	0.000255	0.00131	CcSEcCtD
Indinavir—Anorexia—Vincristine—lymphatic system cancer	0.000255	0.00131	CcSEcCtD
Indinavir—Body temperature increased—Bleomycin—lymphatic system cancer	0.000254	0.0013	CcSEcCtD
Indinavir—Insomnia—Carmustine—lymphatic system cancer	0.000253	0.0013	CcSEcCtD
Indinavir—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000253	0.0013	CcSEcCtD
Indinavir—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000252	0.00129	CcSEcCtD
Indinavir—Paraesthesia—Carmustine—lymphatic system cancer	0.000252	0.00129	CcSEcCtD
Indinavir—Dyspnoea—Carmustine—lymphatic system cancer	0.00025	0.00128	CcSEcCtD
Indinavir—Somnolence—Carmustine—lymphatic system cancer	0.000249	0.00128	CcSEcCtD
Indinavir—Anorexia—Mitoxantrone—lymphatic system cancer	0.000248	0.00128	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000244	0.00125	CcSEcCtD
Indinavir—Decreased appetite—Carmustine—lymphatic system cancer	0.000243	0.00125	CcSEcCtD
Indinavir—Insomnia—Vincristine—lymphatic system cancer	0.000242	0.00124	CcSEcCtD
Indinavir—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000242	0.00124	CcSEcCtD
Indinavir—Paraesthesia—Vincristine—lymphatic system cancer	0.00024	0.00124	CcSEcCtD
Indinavir—Pain—Carmustine—lymphatic system cancer	0.00024	0.00123	CcSEcCtD
Indinavir—Constipation—Carmustine—lymphatic system cancer	0.00024	0.00123	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000237	0.00122	CcSEcCtD
Indinavir—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000236	0.00122	CcSEcCtD
Indinavir—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000234	0.0012	CcSEcCtD
Indinavir—Decreased appetite—Vincristine—lymphatic system cancer	0.000232	0.0012	CcSEcCtD
Indinavir—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000232	0.00119	CcSEcCtD
Indinavir—Somnolence—Mitoxantrone—lymphatic system cancer	0.000232	0.00119	CcSEcCtD
Indinavir—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000231	0.00119	CcSEcCtD
Indinavir—Feeling abnormal—Carmustine—lymphatic system cancer	0.000231	0.00119	CcSEcCtD
Indinavir—Fatigue—Vincristine—lymphatic system cancer	0.000231	0.00119	CcSEcCtD
Indinavir—Asthenia—Bleomycin—lymphatic system cancer	0.00023	0.00118	CcSEcCtD
Indinavir—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000229	0.00118	CcSEcCtD
Indinavir—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000229	0.00118	CcSEcCtD
Indinavir—Constipation—Vincristine—lymphatic system cancer	0.000229	0.00118	CcSEcCtD
Indinavir—Pain—Vincristine—lymphatic system cancer	0.000229	0.00118	CcSEcCtD
Indinavir—Pruritus—Bleomycin—lymphatic system cancer	0.000227	0.00117	CcSEcCtD
Indinavir—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000226	0.00116	CcSEcCtD
Indinavir—Fatigue—Mitoxantrone—lymphatic system cancer	0.000225	0.00115	CcSEcCtD
Indinavir—Pancreatitis—Methotrexate—lymphatic system cancer	0.000224	0.00115	CcSEcCtD
Indinavir—Constipation—Mitoxantrone—lymphatic system cancer	0.000223	0.00115	CcSEcCtD
Indinavir—Pain—Mitoxantrone—lymphatic system cancer	0.000223	0.00115	CcSEcCtD
Indinavir—Body temperature increased—Carmustine—lymphatic system cancer	0.000221	0.00114	CcSEcCtD
Indinavir—Abdominal pain—Carmustine—lymphatic system cancer	0.000221	0.00114	CcSEcCtD
Indinavir—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000219	0.00112	CcSEcCtD
Indinavir—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000215	0.0011	CcSEcCtD
Indinavir—Dysuria—Methotrexate—lymphatic system cancer	0.000213	0.0011	CcSEcCtD
Indinavir—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000213	0.0011	CcSEcCtD
Indinavir—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000212	0.00109	CcSEcCtD
Indinavir—Abdominal pain—Vincristine—lymphatic system cancer	0.000211	0.00109	CcSEcCtD
Indinavir—Body temperature increased—Vincristine—lymphatic system cancer	0.000211	0.00109	CcSEcCtD
Indinavir—Urticaria—Mitoxantrone—lymphatic system cancer	0.000207	0.00106	CcSEcCtD
Indinavir—Hypersensitivity—Carmustine—lymphatic system cancer	0.000206	0.00106	CcSEcCtD
Indinavir—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000206	0.00106	CcSEcCtD
Indinavir—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000206	0.00106	CcSEcCtD
Indinavir—Pneumonia—Methotrexate—lymphatic system cancer	0.000205	0.00105	CcSEcCtD
Indinavir—Vomiting—Bleomycin—lymphatic system cancer	0.000204	0.00105	CcSEcCtD
Indinavir—Rash—Bleomycin—lymphatic system cancer	0.000202	0.00104	CcSEcCtD
Indinavir—Dermatitis—Bleomycin—lymphatic system cancer	0.000202	0.00104	CcSEcCtD
Indinavir—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000202	0.00104	CcSEcCtD
Indinavir—Asthenia—Carmustine—lymphatic system cancer	0.000201	0.00103	CcSEcCtD
Indinavir—Renal failure—Methotrexate—lymphatic system cancer	0.0002	0.00103	CcSEcCtD
Indinavir—Hypersensitivity—Vincristine—lymphatic system cancer	0.000197	0.00101	CcSEcCtD
Indinavir—Sweating—Methotrexate—lymphatic system cancer	0.000195	0.001	CcSEcCtD
Indinavir—Haematuria—Methotrexate—lymphatic system cancer	0.000194	0.000998	CcSEcCtD
Indinavir—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000192	0.00099	CcSEcCtD
Indinavir—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000192	0.000987	CcSEcCtD
Indinavir—Asthenia—Vincristine—lymphatic system cancer	0.000192	0.000987	CcSEcCtD
Indinavir—Diarrhoea—Carmustine—lymphatic system cancer	0.000192	0.000986	CcSEcCtD
Indinavir—Nausea—Bleomycin—lymphatic system cancer	0.000191	0.00098	CcSEcCtD
Indinavir—Asthenia—Mitoxantrone—lymphatic system cancer	0.000187	0.000961	CcSEcCtD
Indinavir—Dizziness—Carmustine—lymphatic system cancer	0.000185	0.000953	CcSEcCtD
Indinavir—Haemoglobin—Methotrexate—lymphatic system cancer	0.000184	0.000944	CcSEcCtD
Indinavir—Diarrhoea—Vincristine—lymphatic system cancer	0.000183	0.000941	CcSEcCtD
Indinavir—Hepatitis—Methotrexate—lymphatic system cancer	0.000183	0.000939	CcSEcCtD
Indinavir—Haemorrhage—Methotrexate—lymphatic system cancer	0.000183	0.000939	CcSEcCtD
Indinavir—Pharyngitis—Methotrexate—lymphatic system cancer	0.000181	0.000932	CcSEcCtD
Indinavir—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00018	0.000928	CcSEcCtD
Indinavir—Urethral disorder—Methotrexate—lymphatic system cancer	0.000179	0.000921	CcSEcCtD
Indinavir—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000178	0.000916	CcSEcCtD
Indinavir—Vomiting—Carmustine—lymphatic system cancer	0.000178	0.000916	CcSEcCtD
Indinavir—Dizziness—Vincristine—lymphatic system cancer	0.000177	0.00091	CcSEcCtD
Indinavir—Rash—Carmustine—lymphatic system cancer	0.000177	0.000908	CcSEcCtD
Indinavir—Dermatitis—Carmustine—lymphatic system cancer	0.000176	0.000908	CcSEcCtD
Indinavir—Headache—Carmustine—lymphatic system cancer	0.000175	0.000903	CcSEcCtD
Indinavir—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000173	0.000888	CcSEcCtD
Indinavir—Vomiting—Vincristine—lymphatic system cancer	0.00017	0.000874	CcSEcCtD
Indinavir—Rash—Vincristine—lymphatic system cancer	0.000169	0.000867	CcSEcCtD
Indinavir—Dermatitis—Vincristine—lymphatic system cancer	0.000168	0.000866	CcSEcCtD
Indinavir—Headache—Vincristine—lymphatic system cancer	0.000168	0.000862	CcSEcCtD
Indinavir—Nausea—Carmustine—lymphatic system cancer	0.000166	0.000856	CcSEcCtD
Indinavir—Vomiting—Mitoxantrone—lymphatic system cancer	0.000166	0.000852	CcSEcCtD
Indinavir—Immune system disorder—Methotrexate—lymphatic system cancer	0.000165	0.000848	CcSEcCtD
Indinavir—Rash—Mitoxantrone—lymphatic system cancer	0.000164	0.000845	CcSEcCtD
Indinavir—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000164	0.000844	CcSEcCtD
Indinavir—Chills—Methotrexate—lymphatic system cancer	0.000164	0.000843	CcSEcCtD
Indinavir—Headache—Mitoxantrone—lymphatic system cancer	0.000163	0.000839	CcSEcCtD
Indinavir—Alopecia—Methotrexate—lymphatic system cancer	0.000161	0.00083	CcSEcCtD
Indinavir—Malnutrition—Methotrexate—lymphatic system cancer	0.000159	0.000818	CcSEcCtD
Indinavir—Nausea—Vincristine—lymphatic system cancer	0.000159	0.000817	CcSEcCtD
Indinavir—Dysgeusia—Methotrexate—lymphatic system cancer	0.000156	0.000801	CcSEcCtD
Indinavir—Nausea—Mitoxantrone—lymphatic system cancer	0.000155	0.000796	CcSEcCtD
Indinavir—Back pain—Methotrexate—lymphatic system cancer	0.000154	0.000791	CcSEcCtD
Indinavir—Vision blurred—Methotrexate—lymphatic system cancer	0.00015	0.000771	CcSEcCtD
Indinavir—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000148	0.000759	CcSEcCtD
Indinavir—Anaemia—Methotrexate—lymphatic system cancer	0.000147	0.000756	CcSEcCtD
Indinavir—Malaise—Methotrexate—lymphatic system cancer	0.000143	0.000737	CcSEcCtD
Indinavir—Vertigo—Methotrexate—lymphatic system cancer	0.000143	0.000735	CcSEcCtD
Indinavir—Cough—Methotrexate—lymphatic system cancer	0.000139	0.000714	CcSEcCtD
Indinavir—Myalgia—Methotrexate—lymphatic system cancer	0.000135	0.000696	CcSEcCtD
Indinavir—Chest pain—Methotrexate—lymphatic system cancer	0.000135	0.000696	CcSEcCtD
Indinavir—Arthralgia—Methotrexate—lymphatic system cancer	0.000135	0.000696	CcSEcCtD
Indinavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000134	0.000691	CcSEcCtD
Indinavir—Discomfort—Methotrexate—lymphatic system cancer	0.000134	0.000688	CcSEcCtD
Indinavir—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00013	0.000667	CcSEcCtD
Indinavir—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000127	0.000654	CcSEcCtD
Indinavir—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000127	0.000653	CcSEcCtD
Indinavir—Skin disorder—Methotrexate—lymphatic system cancer	0.000126	0.000648	CcSEcCtD
Indinavir—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000125	0.000645	CcSEcCtD
Indinavir—Anorexia—Methotrexate—lymphatic system cancer	0.000124	0.000636	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000118	0.000608	CcSEcCtD
Indinavir—Insomnia—Methotrexate—lymphatic system cancer	0.000117	0.000604	CcSEcCtD
Indinavir—Paraesthesia—Methotrexate—lymphatic system cancer	0.000117	0.000599	CcSEcCtD
Indinavir—Dyspnoea—Methotrexate—lymphatic system cancer	0.000116	0.000595	CcSEcCtD
Indinavir—Somnolence—Methotrexate—lymphatic system cancer	0.000115	0.000593	CcSEcCtD
Indinavir—Dyspepsia—Methotrexate—lymphatic system cancer	0.000114	0.000587	CcSEcCtD
Indinavir—Decreased appetite—Methotrexate—lymphatic system cancer	0.000113	0.00058	CcSEcCtD
Indinavir—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000112	0.000576	CcSEcCtD
Indinavir—Fatigue—Methotrexate—lymphatic system cancer	0.000112	0.000575	CcSEcCtD
Indinavir—Pain—Methotrexate—lymphatic system cancer	0.000111	0.000571	CcSEcCtD
Indinavir—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000107	0.00055	CcSEcCtD
Indinavir—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000106	0.000546	CcSEcCtD
Indinavir—Urticaria—Methotrexate—lymphatic system cancer	0.000103	0.00053	CcSEcCtD
Indinavir—Abdominal pain—Methotrexate—lymphatic system cancer	0.000103	0.000528	CcSEcCtD
Indinavir—Body temperature increased—Methotrexate—lymphatic system cancer	0.000103	0.000528	CcSEcCtD
Indinavir—Hypersensitivity—Methotrexate—lymphatic system cancer	9.56e-05	0.000492	CcSEcCtD
Indinavir—Asthenia—Methotrexate—lymphatic system cancer	9.31e-05	0.000479	CcSEcCtD
Indinavir—Pruritus—Methotrexate—lymphatic system cancer	9.18e-05	0.000472	CcSEcCtD
Indinavir—Diarrhoea—Methotrexate—lymphatic system cancer	8.88e-05	0.000457	CcSEcCtD
Indinavir—Dizziness—Methotrexate—lymphatic system cancer	8.58e-05	0.000441	CcSEcCtD
Indinavir—Vomiting—Methotrexate—lymphatic system cancer	8.25e-05	0.000424	CcSEcCtD
Indinavir—Rash—Methotrexate—lymphatic system cancer	8.18e-05	0.000421	CcSEcCtD
Indinavir—Dermatitis—Methotrexate—lymphatic system cancer	8.17e-05	0.00042	CcSEcCtD
Indinavir—Headache—Methotrexate—lymphatic system cancer	8.13e-05	0.000418	CcSEcCtD
Indinavir—Nausea—Methotrexate—lymphatic system cancer	7.71e-05	0.000396	CcSEcCtD
